Exciva GmbH, a biopharmaceutical innovator focusing on neuropsychiatric conditions, has successfully secured €51 million in a Series B financing round. This funding will significantly advance its clinical program aimed at alleviating agitation in Alzheimer’s disease. The financing round was led by Gimv and EQT Life Sciences, with participation from a robust coalition of new and existing investors, including Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, and Modi VC, alongside prior backer LBBW.
Funding Details and Strategic Implications
Andera Partners, which has been a foundational investor in Exciva since its seed and Series A stages in 2021, reaffirmed its commitment by reinvesting in this latest round. The raised capital will primarily support a Phase 2 clinical trial evaluating Exciva’s lead candidate, Deraphan, for treating agitation in Alzheimer’s patients. With a successful Phase 1 trial already completed, showcasing both safety and tolerability, Exciva is poised for a promising leap forward.
The Promise of Deraphan
Deraphan is an innovative combination therapy that merges two clinically validated compounds, including a novel chemical entity (NCE). This combination has shown potential for enhanced efficacy and a favorable risk/benefit profile compared to existing treatments. The Phase 2 trial will be conducted across Europe, the UK, the US, and Canada, emphasizing Exciva’s commitment to a global approach in tackling this pressing health challenge.
Leadership Insights
François Conquet, CEO of Exciva, expressed enthusiasm about the funding, highlighting its validation of the company’s promising product pipeline. He stated, “If the results of the Phase 2 trial are positive, it will be a significant step forward in symptomatic treatment options for patients with Alzheimer’s disease.” This reflects the critical need for new therapies in an area with substantial unmet medical needs.
Raphaël Wisniewski, Partner at Andera Partners, echoed this sentiment, emphasizing the importance of backing from reputable European investors. He noted the significance of this funding not just for Exciva, but for the broader goal of addressing agitation in Alzheimer’s disease—a condition that affects numerous patients and their families.
Board Composition and Governance
Following the Series B funding, Exciva’s board of directors will see representation from various stakeholders, including Raphaël Wisniewski from Andera Partners, Philip Scheltens from EQT Life Sciences, Andreas Jurgeit from Gimv, Aidan King from Fountain Healthcare, independent board member Vikram Sudarsan, and CEO François Conquet. This diverse board composition will bring a wealth of experience to guide Exciva as it navigates the complexities of clinical development and market introduction.
Background on Exciva and Its Mission
Founded in 2016 by Drs. Anton Bespalov, Hans Moebius, and Rao Vepachedu, Exciva aims to address neuropsychiatric symptoms associated with Alzheimer’s disease dementia and other neurological disorders. The company is headquartered in Heidelberg, Germany, and leverages its innovative discovery capabilities to develop effective treatments that improve patient quality of life.
The Role of Andera Partners
With nearly 25 years of expertise, Andera Partners stands as a significant player in private equity investments across Europe and North America. Managing over €5.1 billion in assets, their investment strategy encompasses various sectors, including life sciences, growth, buyout capital, and ecological transition. The firm emphasizes a collaborative approach, working closely with portfolio companies to achieve sustainable growth.
Commitment to Collaboration and Growth
Andera Partners’ philosophy is built on a strong partnership model, fostering collaboration between entrepreneurs and investment professionals. This “Power of And” ethos reflects their commitment to collective engagement, ultimately driving performance and success for their investors and the companies they support.
The Road Ahead for Alzheimer’s Treatment
As Exciva embarks on this critical Phase 2 trial, the importance of new treatment options for Alzheimer’s-related agitation cannot be overstated. With the rising prevalence of Alzheimer’s disease globally, innovative solutions like Deraphan could play a pivotal role in enhancing patient care.
Key Takeaways:
- Exciva has raised €51 million to advance its treatment program for Alzheimer’s-related agitation.
- The funding will support a Phase 2 clinical trial for its lead candidate, Deraphan.
- The company is backed by a strong coalition of investors, signaling confidence in its potential.
- Successful outcomes from the trial could significantly improve treatment options for Alzheimer’s patients.
In conclusion, Exciva’s recent funding marks a significant milestone in the fight against Alzheimer’s disease. With robust backing and a promising therapeutic candidate, the company is well-positioned to make impactful strides in neuropsychiatric care. The journey ahead holds the potential for transformative change in the lives of countless patients and their families.
Read more → www.pharmabiz.com